Trial · NCT03238898
Botulinum Toxin for Cramps in Diabetic Neuropathy
NCT03238898, Phase 2, Completed, Presidio Ospedaliero Garibaldi-Centro
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Botulinum Toxin for Cramps in Diabetic Neuropathy. Trials, record NCT03238898. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03238898
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Botulinum Toxin for Cramps in Diabetic Neuropathy
- NCT number
- NCT03238898
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 50 participants, actual
- Lead sponsor
- Presidio Ospedaliero Garibaldi-Centro
- Conditions
- Muscle Cramps Aggravated, Diabetes Mellitus
- Interventions
- Botulinum toxin type A, Normal saline
- First posted
- 2017-08-03
- Last updated
- 2017-08-03
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | pain intensity on a 0-10 severity scale | 20 weeks | the intensity of pain was rated on a scale 0 to 10, with 0 indicating no pain and 10 indicating "the worst pain imaginable" |
| Secondary | cramp frequency | 20 weeks | the changes in cramp frequency, the Cramp Severity Scale (CSS) were evaluated over the course of 20 weeks after BoNT/A administration |
| Secondary | the Cramp Severity Scale (CSS) | 20 weeks | the changes in the Cramp Severity Scale (CSS) were evaluated over the course of 20 weeks after BoNT/A administration |
| Secondary | the Cramp Threshold Frequency (CTF) | 20 weeks | the changes in the Cramp Threshold Frequency were evaluated over the course of 20 weeks after BoNT/A administration |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 9029067 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03238898
GET https://conductscience.org/api/trials/v1/NCT03238898/registered